Bruno Nunes Ferraz de Abreu , Dina Andressa Martins Monteiro , Ivna Lacerda Pereira Nóbrega , Igor Bessa Santiago , Paula Camila Alves de Assis Pereira Matos , Fernanda Martins Maia Carvalho , Gabriela Joca Martins , José Artur D’Almeida , Milena Sales Pitombeira
{"title":"NMOSD伴区域后发综合征患者首次发病的历程,单中心回顾性研究","authors":"Bruno Nunes Ferraz de Abreu , Dina Andressa Martins Monteiro , Ivna Lacerda Pereira Nóbrega , Igor Bessa Santiago , Paula Camila Alves de Assis Pereira Matos , Fernanda Martins Maia Carvalho , Gabriela Joca Martins , José Artur D’Almeida , Milena Sales Pitombeira","doi":"10.1016/j.msard.2025.106605","DOIUrl":null,"url":null,"abstract":"<div><div>One of the typical manifestations of Neuromyelitis optica spectrum disorder (NMOSD) is the Area Postrema syndrome (APS), defined by nausea, vomiting or hiccups lasting longer than 48 h. This syndrome is usually misdiagnosed and associated with diagnosis delay. This study aims to understand whether APS as the initial attack is associated with a longer time to first neurology visit and diagnosis in a Brazilian population. Data from 74 patients was collected from patient records and patient interviews. The most common first manifestation was optic neuritis 29 (39 %) and isolated APS was the first clinical syndrome in 12 patients (16 %). Median time to first medical care was 7 days in the APS group and 4.5 days in the non-APS group (<em>p</em> = 0.87). Median time for first neurological assessment was 232.5 days in the APS group while it was 25 days in the non-APS group (<em>p</em> < 0.001). The median time to first disease modifying drug was 344 days in the APS group and 164 days in the non-APS group (<em>p</em> = 0.051). All 12 APS patients had another attack before diagnosis with a median attack number before diagnosis of 3 (range 2–5) and 2 (range 1–5) in the non-APS group (<em>p</em> = 0.001). Acute treatment was performed in 45 (72.5 %) of non-APS group while no patients on the APS group had received acute treatment (<em>p</em> = 0.001). The APS as the first NMOSD manifestation was associated with delay to neurology assessment, higher number of attacks before diagnosis and untreated attacks.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"102 ","pages":"Article 106605"},"PeriodicalIF":2.9000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The journey of the patient living with NMOSD with area postrema syndrome as the inaugural Attack, a single center retrospective study\",\"authors\":\"Bruno Nunes Ferraz de Abreu , Dina Andressa Martins Monteiro , Ivna Lacerda Pereira Nóbrega , Igor Bessa Santiago , Paula Camila Alves de Assis Pereira Matos , Fernanda Martins Maia Carvalho , Gabriela Joca Martins , José Artur D’Almeida , Milena Sales Pitombeira\",\"doi\":\"10.1016/j.msard.2025.106605\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>One of the typical manifestations of Neuromyelitis optica spectrum disorder (NMOSD) is the Area Postrema syndrome (APS), defined by nausea, vomiting or hiccups lasting longer than 48 h. This syndrome is usually misdiagnosed and associated with diagnosis delay. This study aims to understand whether APS as the initial attack is associated with a longer time to first neurology visit and diagnosis in a Brazilian population. Data from 74 patients was collected from patient records and patient interviews. The most common first manifestation was optic neuritis 29 (39 %) and isolated APS was the first clinical syndrome in 12 patients (16 %). Median time to first medical care was 7 days in the APS group and 4.5 days in the non-APS group (<em>p</em> = 0.87). Median time for first neurological assessment was 232.5 days in the APS group while it was 25 days in the non-APS group (<em>p</em> < 0.001). The median time to first disease modifying drug was 344 days in the APS group and 164 days in the non-APS group (<em>p</em> = 0.051). All 12 APS patients had another attack before diagnosis with a median attack number before diagnosis of 3 (range 2–5) and 2 (range 1–5) in the non-APS group (<em>p</em> = 0.001). Acute treatment was performed in 45 (72.5 %) of non-APS group while no patients on the APS group had received acute treatment (<em>p</em> = 0.001). The APS as the first NMOSD manifestation was associated with delay to neurology assessment, higher number of attacks before diagnosis and untreated attacks.</div></div>\",\"PeriodicalId\":18958,\"journal\":{\"name\":\"Multiple sclerosis and related disorders\",\"volume\":\"102 \",\"pages\":\"Article 106605\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-07-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Multiple sclerosis and related disorders\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2211034825003475\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple sclerosis and related disorders","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2211034825003475","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
The journey of the patient living with NMOSD with area postrema syndrome as the inaugural Attack, a single center retrospective study
One of the typical manifestations of Neuromyelitis optica spectrum disorder (NMOSD) is the Area Postrema syndrome (APS), defined by nausea, vomiting or hiccups lasting longer than 48 h. This syndrome is usually misdiagnosed and associated with diagnosis delay. This study aims to understand whether APS as the initial attack is associated with a longer time to first neurology visit and diagnosis in a Brazilian population. Data from 74 patients was collected from patient records and patient interviews. The most common first manifestation was optic neuritis 29 (39 %) and isolated APS was the first clinical syndrome in 12 patients (16 %). Median time to first medical care was 7 days in the APS group and 4.5 days in the non-APS group (p = 0.87). Median time for first neurological assessment was 232.5 days in the APS group while it was 25 days in the non-APS group (p < 0.001). The median time to first disease modifying drug was 344 days in the APS group and 164 days in the non-APS group (p = 0.051). All 12 APS patients had another attack before diagnosis with a median attack number before diagnosis of 3 (range 2–5) and 2 (range 1–5) in the non-APS group (p = 0.001). Acute treatment was performed in 45 (72.5 %) of non-APS group while no patients on the APS group had received acute treatment (p = 0.001). The APS as the first NMOSD manifestation was associated with delay to neurology assessment, higher number of attacks before diagnosis and untreated attacks.
期刊介绍:
Multiple Sclerosis is an area of ever expanding research and escalating publications. Multiple Sclerosis and Related Disorders is a wide ranging international journal supported by key researchers from all neuroscience domains that focus on MS and associated disease of the central nervous system. The primary aim of this new journal is the rapid publication of high quality original research in the field. Important secondary aims will be timely updates and editorials on important scientific and clinical care advances, controversies in the field, and invited opinion articles from current thought leaders on topical issues. One section of the journal will focus on teaching, written to enhance the practice of community and academic neurologists involved in the care of MS patients. Summaries of key articles written for a lay audience will be provided as an on-line resource.
A team of four chief editors is supported by leading section editors who will commission and appraise original and review articles concerning: clinical neurology, neuroimaging, neuropathology, neuroepidemiology, therapeutics, genetics / transcriptomics, experimental models, neuroimmunology, biomarkers, neuropsychology, neurorehabilitation, measurement scales, teaching, neuroethics and lay communication.